Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11152
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRajarubendra, Nieroshanen
dc.contributor.authorLawrentschuk, Nathan Len
dc.contributor.authorBolton, Damien Men
dc.contributor.authorKlotz, Laurenceen
dc.contributor.authorDavis, Ian Den
dc.date.accessioned2015-05-16T00:44:22Z
dc.date.available2015-05-16T00:44:22Z
dc.date.issued2010-11-10en
dc.identifier.citationBJU International 2010; 107(7): 1046-51en
dc.identifier.govdoc21070575en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11152en
dc.description.abstractA better understanding of the immune processes in the pathogenesis and progression of prostate cancer (CaP) may point the way towards improved treatment modalities. The challenge is to amplify immune responses to combat tumour escape mechanisms. Infection and inflammation may have a role in prostate carcinogenesis, including the newly discovered xenotropic murine leukaemia virus (XMRV). These inflammatory states damage defence mechanisms and induce a high proliferative state favouring further mutation and impaired immune surveillance. With this knowledge we are able to explore the use of immunotherapy to rejuvenate the immune system in combating CaP. Recently Sipuleucel-T, an immunotherapeutic agent for metastatic androgen independent CaP, has resulted in improved survival and might be the first immunotherapeutic agent to obtain approval for CaP treatment. This short review will focus on the growing body of evidence suggesting an immunity-based link between CaP and inflammation and infection.en
dc.language.isoenen
dc.subject.otherCancer Vaccines.therapeutic useen
dc.subject.otherEpidemiologic Methodsen
dc.subject.otherHumansen
dc.subject.otherImmunotherapy.methodsen
dc.subject.otherMaleen
dc.subject.otherProstatic Neoplasms.immunology.therapyen
dc.subject.otherT-Lymphocytesen
dc.subject.otherTissue Extracts.therapeutic useen
dc.titleProstate cancer immunology - an update for Urologists.en
dc.typeJournal Articleen
dc.identifier.journaltitleBJU Internationalen
dc.identifier.affiliationDepartment of Surgery, University of Melbourne, Austin Hospital, Urology Unit, Australiaen
dc.identifier.doi10.1111/j.1464-410X.2010.09820.xen
dc.description.pages1046-51en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21070575en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.